Naftali Kaminski
Pulmonary Disease · New Haven, CTNPI 1376918870
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $174,968 of the $179,905 with a category attached, or 97.3%. Boehringer Ingelheim accounts for 80.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $111,689 and has fallen 99.5% since, to $595 in 2025. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $2949.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$145K
- Merck$19K
- Astrazeneca UK Limited$9K
- GSK$5K
- Astrazeneca AB$2K
- CSL Behring$940
- plus $56 from 1 others
Across 3 payments — averaging $277,605 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$653K
- Boehringer Ingelheim$179K
What the payments were for
- Consulting fees$174,96897%
- Speaking & faculty fees$9401%
- Travel & lodging$2,3241%
- Food & beverage$1,6731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 29 | $144,549 |
| Merck | 24 | $18,710 |
| Astrazeneca UK Limited | 4 | $8,850 |
| GSK | 1 | $4,550 |
| Astrazeneca AB | 1 | $2,250 |
| CSL Behring | 1 | $940 |
| Bristol Myers Squibb | 1 | $56 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$5,277
How this compares
$179,905 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in New Haven
- Geoffrey ChuppNew Haven$1.2M
- Michael ImevboreNew Haven$323K
- Lauren CohnNew Haven$134K
- Erica HerzogNew Haven$74K
- Mridu GulatiNew Haven$53K
- Jennifer PossickNew Haven$48K
- Carolyn RochesterNew Haven$29K
- Maor SaulerNew Haven$18K
- Jonathan KoffNew Haven$15K
- Olurotimi AdekoluNew Haven$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.